Content area
Abstract
The AXcess Advantage Program/XEOMIN(R) Patient Assistance Plan will assist patients with their out of pocket prescription expenses by paying up to 20% of each XEOMIN(R) prescription.(i) The objective of the program is to broaden the access and availability to patients who could benefit from XEOMIN(R) therapy.
XEOMIN(R) as a treatment for focal spasticity has been studied in association with usual standard care regimens and is not intended as a replacement for these treatment modalities. XEOMIN(R) is not likely to be effective at a joint affected by a fixed contracture. XEOMIN(R) may only be used by physicians with suitable qualifications and proven experience in the application of Botulinum toxin type A and in the use of the necessary equipment, e.g. EMG (electromyography).